Loss narrows sharply. Bicycle Therapeutics plc (NASDAQ: BCYC) reported a loss of $0.29 per share for Q4 2025, narrower than the estimated loss of $0.95, 69.6% narrower. The biotechnology company posted a net loss of $20.2 million for the quarter. Eleven analysts had projected losses ranging from $0.79 to $1.18 per share. The result marks significant improvement from the year-ago loss of $0.81 per share.
Revenue surges past consensus. Revenue reached $48.0 million, crushing the $7.1 million analyst consensus by 578%. The top-line figure represents a dramatic acceleration from the prior quarter’s $48.0 million and the year-ago period’s $3.7 million. Analyst estimates had ranged from $2.9 million to $15.0 million, with the actual result exceeding even the most optimistic projection by more than threefold.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.